Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.</li><li>After 16 weeks of treatment, vanoglipel showed reductions in HbA1c of 0.37%, 0.41%, and 0.54% at weeks 4, 8, and 16, from a baseline of 6.99%.</li><li>Vanoglipel also significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L.</li></ul>

In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.After 16 weeks of treatment, vanoglipel showed reductions in HbA1c of 0.37%, 0.41%, and 0.54% at weeks 4, 8, and 16, from a baseline of 6.99%.Vanoglipel also significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L.

MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD 